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Background: Intraneuronal inclusions of TAR DNA-binding protein 43 (TDP-43) have been found in the majority of
Amyotrophic Lateral Sclerosis (ALS) patients. Mutations in the gene encoding TDP-43 cause familial ALS. Transgenic
mice expressing mutant TDP-43 with one such mutation (TDP-43 (A315T)) under control of the murine prion
promoter develop motor symptoms, but their use is currently hampered by sudden death. We aimed to understand
and overcome the cause of sudden death in TDP-43 (A315T) mice. Since intestinal obstruction was suspected to be
the cause, intestinal motility of TDP-43 (A315T) mice was studied in an ex-vivo pellet propulsion assay. The effect on
the enteric and motor phenotype was assessed, both in animals on normal chow or on a jellified fiber deprived
diet, aimed at preventing intestinal obstruction.
Results: The frequency of the propulsive motor complexes was significantly reduced in the colon of TDP-43 (A315T)
compared to non transgenic (NTG) mice. Immunohistochemistry revealed significant enlargement in size and
reduction in number of the nitric oxide synthase (NOS) neurons in the myenteric plexus of TDP-43 (A315T) mice.
Prevention of intestinal obstruction by jellified food abolished sudden death, allowing the motor phenotype to
develop and slowly progress with a more pronounced degeneration of upper and lower motor axons. A
downregulation of endogenous TDP-43 mRNA and protein levels was observed prior to neurodegeneration.
Conclusion: TDP-43 (A315T) mice suffer from intestinal dysmotility due to degeneration of NOS neurons in the
myenteric plexus. Feeding the mice jellified food prevents sudden death and allows the motor phenotype to
progress.
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Transactive response DNA-binding protein (TDP-43) is
involved in the pathogenesis of several neurodegerative
disorders, primarily in Amyotrophic Lateral Sclerosis
(ALS) and Frontotemporal Lobar Degeneration (FTLD)
[1]. TDP-43 inclusions have also been observed in Alzheimer’s
disease [2], Guam parkinsonism-dementia complex [3],
Huntington’s disease [4] and Hippocampal sclerosis [2].
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article, unless otherwise stated.where it regulates transcription and splicing, and the cyto-
plasm, where it has a role in RNA transport, mRNA sta-
bility and is a component of stress granules [1,5]. Most
ALS patients show TDP-43 pathology on postmortem tis-
sue: TDP-43 is abnormally ubiquitinated, phosphorylated,
cleaved, translocated to the cytoplasm and found in aggre-
gates in the (upper and lower) motor neurons [1]. About 2
to 5% of the familial ALS cases are due to mutations in
the gene encoding TDP-43 with clustering of mutations in
its C-terminal region [6-8]. To unravel the disease mecha-
nisms of TDP-43 induced neurodegeneration, several
transgenic mouse models have been generated [9-18]. In
2009, Wegorzewska et al. [15] reported a mouse (available
from The Jackson laboratory, stock number 010700) withtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of the mouse prion promoter, leading to a threefold over-
expression of TDP-43 in spinal cord and brain. These
mice were reported to develop gait abnormalities from 3
to 4 months on, a swimming gait accompanied by weight
loss at 4.5 months and to survive 154 ± 19 days. At the
pathological level, there was a 20% loss of lower motor
neurons and a 50% loss of upper motor axons in the spinal
cord. However, we and others have observed a sudden
death in these mice, prior to the development of full
neurological symptoms [19-21].
The aim of this study was to identify the pathological
mechanism behind this sudden death and provide a so-
lution to allow the neurodegeration to develop further
and render this transgenic mouse a useful model to
study TDP-43 induced neurodegeneration.
Results
Sudden death in TDP-43 (A315T) mice is due to intestinal
dysfunction
We observed a sexual dimorphism in disease onset and
survival of TDP-43 (A315T) mice, as reported previously
[19]. Male mice had a median survival of 84 days,
whereas females survived for 126 days (Figure 1A). This
difference could not be explained by a difference in
TDP-43 expression levels as assessed by Western blot
analysis of spinal cord lysates. Although the disease on-
set was quite variable, most mice died within a week
after onset of swimming gait abnormalities (Figure 1B).
Contrary to mutant SOD1 mice, TDP-43 (A315T) mice
died suddenly before the development of end stage (ES)
motor symptoms. Sometimes, mice even died before the
onset of neurologic abnormalities. These animals looked
lethargic, a phenotype that is not directly compatible
with ALS. Upon inspection, these mice appeared to have
an extremely rigid abdomen indicative of intestinal ob-
struction, which was confirmed at autopsy. Even before
the onset of motor symptoms, intestinal abnormalities
with signs of pseudo-obstruction, thinned colon, en-
larged caecum and distension of the small intestines
could be observed (Figure 1C). The intestinal distension
seemed most pronounced at the ileocaecal junction and
was found to be progressive with age.
To understand the mechanisms underlying the intes-
tinal dysmotility, we performed video experiments to
measure the intestinal propulsion (Figure 1D) and also
examined the myenteric plexus by immunohistochemis-
try. The number of contractions induced by the presence
of an artificial pellet inserted into the isolated colon was
significantly reduced in TDP-43 (A315T) mice, com-
pared to NTG littermates (Figure 1D and E, upper
graph). The force of muscle contractions, as measured
by the displacement of the pellet per contraction, was
not affected in TDP-43 (A315T) mice compared to NTG(Figure 1D and E, lower graph), indicating that the peri-
staltic malfunction was of pure intrinsic neuronal origin.
Immunostaining with a specific human TDP-43 antibody
[22] confirmed the selective expression of the transgene
in the nuclei of myenteric neurons (and glial cells),
which is in line with a prion promoter (Prnp) pattern
(Figure 2A and A’, 2B and B’). Although no major loss of
enteric neurons was detected (HuCD positive neurons
per ganglion: 37.1 ± 3.4 vs. 33.9 ± 2.5 for TDP-43
(A315T) and NTG mice, respectively), one specific
population, the nitric-oxide synthase (NOS) expressing
neurons, was severely affected in terminal ileum and
colon. Their number was significantly reduced (8.4 ± 1.7
vs. 15.7 ± 1.9 per ganglion), and an enlarged swollen ap-
pearance of NOS neurons was noted (Figure 2C and C’),
especially as mice got older. On the other hand, a staining
for excitatory neurons, using a choline acetyltransferase
(ChAT) antibody did not reveal any obvious differences
between TDP-43 (A315T) and NTG mice (Figure 2D
and D’). Furthermore, the enteric glial cell network that
normally surrounds individual nerve cells was also se-
verely distorted as shown by GFAP immunostaining
(Figure 2A and A’, 2B and B’).
Downregulation of endogenous TDP-43 at mRNA and
protein level
Immunostainings using an antibody that recognizes the
C-terminal part of both mouse and human TDP-43
(12892-1-AP) in NTG (Figure 3A, upper panels) and
TDP-43 (A315T) mice (Figure 3A, middle panels), revealed
that most neurons from TDP-43 (A315T) mice retain the
nuclear TDP-43 expression, even at advanced disease stage.
A (partial) loss of nuclear TDP-43 (Figure 3A, middle
panels) and (intranuclear) TDP-43 inclusions (Figure 3A,
lower panels) were only rarely seen in the TDP-43
(A315T) mice.
We could also detect a clear downregulation at the
mRNA level of endogenous TDP-43 due to the overex-
pression of human mutant TDP-43 [10,23,24]. Using qPCR,
we measured a 20% reduction of endogenous TDP-43
mRNA in the spinal cord of TDP-43 (A315T) mice com-
pared to NTG littermates (Figure 3B) and a 31% reduc-
tion in the brain (Figure 3C). This downregulation of
endogenous TDP-43 was also confirmed at the protein
level by Western blot, where we detected a reduction of
48% in the spinal cord (Figure 3D and E).
To assess whether this downregulation of endogenous
TDP-43 was associated with downstream splicing de-
fects, we measured sortilin exon 17 b expression. In line
with previous studies [25,26], we found a decrease in the
levels of the splice variant of sortilin 1 with exon 17b in-
clusion (Sort1 + Ex17b) in the TDP-43 (A315T) mice
(Figure 3F). Since it has been shown [25,26] that down-
regulation of TDP-43 in mouse N2a cells, leads to an
Figure 1 (See legend on next page.)
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Figure 1 Sudden death in TDP-43 (A315T) mice is due to intestinal dysfunction. A: The survival of male TDP-43 (A315T) mice (median of
84 days, n = 53) differed significantly from female TDP-43 (A315T) mice (median of 126 days, n = 38) (p = 0.0004) and was for both genders very
variable. B: Despite the variation in survival, the disease duration for both genders was very short: most mice died within a week after the onset
of swimming gait abnormalities (median = 7 days for the males and median = 11 days for the females, n = 22 male and 15 female mice, p = 0.29).
C: Comparison of intestines between NTG and TDP-43 (A315T) mice. Left: TDP-43 (A315T) mice displayed enlarged ileum (red arrowhead) and
caecum (white arrow), which are easily detectable as compared to the normal-size ileum and colon from NTG mice. Right: Picture of the entire
colon revealed no shortening in TDP-43 (A315T) compared to NTG mice. Note the absence of inflammatory patches or bleeding in the colon of
TDP-43 (A315T) mice. D: Propulsion in colon segments from TDP-43 (A315T) and NTG mice. Recordings were made after the pellet was introduced
in the colon (upper panels). Spatiotemporal map depicting the diameter of the colon segment in TDP-43 (A315T) (right) and NTG (left) mice (bar
in x: 10 mm; bar in y: 100 s). E: The graphs show a significant reduction (p = 0.006) of frequency of contractions (upper graph) but not of force of
muscle contraction (lower graph) between TDP-43 (A315T) (red bar) and NTG (grey bar) mice. n values indicate the number of mice from which
the colon segments were analyzed.
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human TDP-43(A315T) overexpression can compensate
for the downregulation of mouse TDP-43.
Effect of gel food on disease progression and
neurodegeneration in TDP-43 (A315T) mice
We sought to prevent the intestinal obstruction by re-
moving non-digestible elements from the food and feed-
ing the mice a nutrient gel (referred to as “gel” food).
This diet was initiated before the development of gait
abnormalities (at the age of 30 days for male and 80 days
for female mice) and compared to the standard chow
(referred to as “normal” food).
The effect of this simple intervention on the motor
phenotype and survival of TDP-43 (A315T) mice was
studied. First of all, gel feeding abolished the occurrence
of sudden death. Instead, a slowly progressive motor
phenotype was observed, resulting in an extended disease
duration after the onset of obvious motor symptoms
(Figure 4A). Both male and female mice developed more
pronounced gait abnormalities with time (see Additional
file 1: movies 1 and 2). After the onset of motor symp-
toms, we observed a slowly progressive weight loss and at-
rophy (of the gastrocnemius muscles). At ES, the mice
were not able to turn from their side anymore and they
had lost up to 40% of their body weight (see Additional
file 1: movies 3 and 4). The disease onset remained ex-
tremely variable, ranging from 58 to 427 days in male
and from 99 to 538 days in female mice (Figure 4B), but
the survival after disease onset was extended with sev-
eral weeks - even months - in the gel fed mice.
Histological analysis revealed a pathological substrate
for the progressive motor phenotype. We could not find
a lower motor neuron cell body loss when counting motor
neurons in the ventral horn of the lumbar spinal cord
(Figure 4C). The percentage of fully denervated neuro-
muscular junctions (NMJ) in the TDP-43 (A315T) mice
was rather limited, but almost doubled in the longer sur-
viving gel fed mice: 20% of denervated NMJ at ES in the
TDP-43 (A315T) mice on gel food, 11.6% in the TDP-43
(A315T) mice with normal food at ES and 3% in NTGmice (Figure 4D). Also, gastrocnemius muscle atrophy
was more pronounced. The serum CK levels at ES did not
differ from NTG mice (p = 0.79). In addition, we could de-
tect a more pronounced loss of upper motor axons in the
lateral corticospinal tract of TDP-43 (A315T) mice receiv-
ing gel food [27] (Figure 4E). Especially, there was a more
pronounced loss of larger axons (Figure 4F). We also ob-
served an increased astrogliosis in the spinal cord of TDP-
43 (A315T) mice put on gel food, compared to mice with
normal food at ES (Figure 4G), illustrating the more ad-
vanced disease state reached.
To test whether the severe enteric nervous system
(ENS) degeneration was progressing further in gel fed
TDP-43 (A315T) mice, we performed immunostainings
of the ENS. As can be appreciated in Figure 5A, the loss
of enteric NOS neurons was also progressive in these
animals, as numbers of NOS neurons were further re-
duced and remnant NOS neurons further enlarged. The
enteric glial network was also more severely disrupted
(Figure 5B). Taken together, feeding the TDP-43 (A315T)
mice gel food abolished the sudden death and allowed a
progressive motor phenotype to develop further.
Discussion
To unravel the disease mechanisms of TDP-43 induced
neurodegeneration, several transgenic mouse models
have been generated. Unfortunately, so far none of them
fulfills the expectations. The TDP-43 (A315T) mice (de-
signed by Wegorzewska et al. [15]) develop motor symp-
toms, but the sudden death, due to intestinal distension
as reported previously [19-21] limits their use.
In this study we unraveled the nature of the intestinal
problems in an ex-vivo pellet study, which revealed a sig-
nificant reduction in the ability to generate propulsive
contractions in these mice. Using immunohistochemical
analysis, we observed a degeneration of NOS neurons in
the ENS, which is responsible for the coordination of
peristaltic movements. NOS neurons are responsible for
inhibitory signaling within the ENS and together with
excitatory neurons finely regulate intestinal peristalsis.
Both excitation and inhibition are quintessential for luminal
Figure 2 (See legend on next page.)
Herdewyn et al. Molecular Neurodegeneration 2014, 9:24 Page 5 of 14
http://www.molecularneurodegeneration.com/content/9/1/24
(See figure on previous page.)
Figure 2 Immunostaining of the myenteric plexus showed degeneration of NOS neurons in the Prnp TDP-43 (A315T) mice. A-A’:
Immunostaining of the myenteric plexus with TDP-43 antibody recognizing mouse and human TDP-43 (m + h, color code: green) revealed
positive staining in the nuclei of all the cells both in NTG (A) and in TDP-43 (A315T) mice (A’). The GFAP staining already reveals a clear difference
between the two genotypes: in A the healthy glia cell network clearly surrounds the enteric neurons, while in A’ the glial network is distorted.
B-B’: Immunostaining of the myenteric plexus with a specific human TDP-43 antibody (hTDP-43, color code: green) confirmed specific expression
of the transgene in the nuclei of neurons and glial cells (GFAP-positive, color code: red) in TDP-43 (A315T) mice (B’) while NTG mice were completely
negative (B). C-C’: Immunostaining revealed significant reduction in number and enlargement in size of NOS neurons (white arrows, color code: red)
in the myenteric plexus of TDP-43 (A315T) (C’) compared to NTG (C) mice. Total neurons were labeled with the panneuronal marker HuCD (C-C’; color
code: green). D-D’: Immunostaining of the myenteric plexus with ChAT (cholinergic neurons, color code: green) and NOS (color code: red) revealed no
significant differences in ChAT staining while again NOS neurons clearly appear fewer and larger (arrows) in TDP-43 (A315T) (D’) compared to NTG (D)
mice. Scale bars: 100 μm.
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ously fail to produce any contractile force, but also lack
of inhibition prevents peristalsis as gut muscle relax-
ation in front of the luminal contents is equally important.
In previous studies, the Prnp promoter was suggested to
drive expression in particular in enteric glial cells [28].
However, we clearly observed a high transgene expression
(of human mutant TDP-43) in the nuclei of neurons of
the myenteric plexus. While writing this manuscript, an
independent study [29] also described the transgene ex-
pression and neurodegeneration of the enteric neurons in
this mouse model as an explanation for the reduced intes-
tinal motility. The authors showed that mutant mice have
a loss in acetylcholinesterase-positive neurons, which are
excitatory, explaining, in part, the reduction in colonic
propulsion. Here, we did not observe any difference in
cholinergic neurons in TDP-43 (A315T) mice, but we
mainly found a loss of NOS neurons, preceded by an in-
crease in their cell soma size. These findings do not ex-
clude each other. In fact, while the loss of NOS neurons
may represent an early event, a later stage of the disease
may be characterized by the impairment of cholinergic
signaling as well, thus also affecting excitatory pathways.
The degeneration of NOS neurons causes the loss of in-
hibitory control leading to abnormalities in intestinal pro-
pulsion, dysmotility and, finally, to pseudo-obstruction
and sudden death. The exact mechanism that leads to the
enlargement and loss of NOS neurons is not clear, but de-
fects in the neuroprotective glial network may be involved,
as demonstrated by GFAP distorted signaling. Also, re-
duced synaptic input could lead to loss of volume con-
straints in neurons. Medina et al. [21] reported a
reduction in synaptophysin in the hippocampus of these
mice, indicating a role of TDP-43 in synaptic function.
Our study indicates that the ENS is vulnerable to the toxic
effects of mutant TDP-43. This is in line with recent evi-
dence showing parallel manifestations of various neuropa-
thologies in the enteric and central nervous systems [30].
However, it remains largely unexplored if the ENS is af-
fected in patients with ALS.
We could confirm the downregulation of endogenous
TDP-43 in spinal cord and brain, both at mRNA andprotein level, supporting a role for autoregulation of
TDP-43 expression. TDP-43 can bind the 3’ UTR of its
own transcript. This leads to decreased expression of en-
dogenous TDP-43 due to the 3-fold overexpression of
exogenous TDP-43 [15]. Since we and others [25,26]
measured a decrease of Sort1 + Ex17b in the brain of hu-
man TDP-43 (A315T) overexpressing mice, in contrast
to the upregulation seen in mouse N2a cells with TDP-
43 knock-down, this suggests that the reduction of
endogenous TDP-43 is overcompensated by the expres-
sion of human mutant TDP-43 (A315T). As suggested
previously [10,23,24], the downregulation of endogen-
ous TDP-43 can contribute to the pathogenesis of neu-
rodegeneration, but so does overcompensation, since a
physiological range of expression, below or above which
pathology develops, appears to be important. In line
with previous studies [15,19], we could detect some loss
of nuclear TDP-43 and (nuclear) TDP-43 inclusions in
TDP-43 (A315T) mice at ES, but both were rare phe-
nomena, suggesting that cytoplasmic mislocalization
and inclusions are not the major cause of toxicity in this
model.
Interestingly, a similar phenomenon of pseudo-obstruction
was described in transgenic mice expressing CAG-
repeats under the control of the Prnp [31]. Severely en-
larged and loss of NOS neurons, together with intestinal
pseudo-obstruction was seen in mice overexpressing the
polyglutamine expansion responsible for SCA7. This
suggests that the ENS is vulnerable to neurodegenera-
tion as well, and may be a readily accessible part of the
nervous system to study mechanisms of neurodegenera-
tion, even in intestinal biopsies obtained from patients
[32]. In addition, TDP-43 (A315T) mice could become a
useful model to study intestinal motility disorders
caused by degeneration, in addition to the developmen-
tal models of intestinal dysfunction.
In this study we succeeded to overcome the sudden
death by feeding the mice gel food and thereby prevent-
ing intestinal constipation. This intervention significantly
extended survival and allowed a progressive motor pheno-
type to develop. Disease progression was associated with a
more pronounced loss of upper and lower motor axons.
Figure 3 (See legend on next page.)
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Figure 3 Downregulation of endogenous TDP-43 at mRNA and protein level. A: Immunostaining with the TDP-43 antibody that recognizes
the C-terminal part of both mouse and human TDP-43 (12892-1-AP) of the ventral horn of the lumbar spinal cord of TDP-43 (A315T) mice at ES
(middle and lower panels) compared to NTG mice (upper panels). Loss of nuclear TDP-43 (middle panels, arrows) and (intranuclear) TDP-43 inclusions
(lower panels, arrows) could be detected, but were rare. For the pictures, both the separate images and the merged are shown (red: TDP-Ab; green:
NeuN; blue: DAPI). Scale bars: 50 μm. B: 20% reduction of the endogenous mouse TDP-43 mRNA in the spinal cord due to the overexpression
of exogenous human TDP-43 in the TDP-43 (A315T) mice (p < 0.0001, n = 3 for each genotype). C: 31% reduction of the endogenous mouse
TDP-43 mRNA in the brain of TDP-43 (A315T) mice (p < 0.0001, n = 3 for each genotype). D-E (D) Representative Western blot of spinal cord
tissue of NTG mice (left), compared to presymptomatic female TDP-43 (A315T) mice (right). The higher band, that is absent in the NTG mice, is
the human TDP-43 protein, containing a Flag-tag. Alfa-tubulin was used for normalization (n = 3). E: Quantification showed a 48% loss of
endogenous TDP-43. F: Downregulation of the levels of Sort1 with exon 17b inclusion in the brain of the TDP-43 (A315T) mice, compared to
NTG mice (n = 3 for each genotype; p = 0.031).
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of lower motor neuron degeneration in the ventral horn
of the spinal cord. Compared to mutant SOD1 mice,
TDP-43 (A315T) mice have limited loss of NMJs. A dys-
functional neuromuscular transmission is not excluded
in the current study and may contribute to the muscle
weakness observed. However, the progressive motor
phenotype observed can most likely be attributed to loss
of upper motor neuron axons. Therefore, TDP-43 (A315T)
mice can be of value in studying the upper motor
neuron degeneration, that is an essential hallmark of
ALS (with and without TDP-43 mutations), but is less
well studied so far. The large variation in disease onset
makes this model less suited for cross breeding experi-
ments, although a similar heterogeneity in disease onset
is also apparent in ALS patients.
Conclusions
In summary, feeding the TDP-43 (A315T) mice jellified
fiber deprived food, abolished sudden death due to intes-
tinal dysmotility and allowed the slowly progressive
upper and lower motor axon phenotype to develop fur-
ther, thus rendering this mouse a suitable model for
TDP-43 induced (upper motor) neurodegeneration.
Materials and methods
Feeding and follow-up of TDP-43 (A315T) mice
The TDP-43 (A315T) mice designed by Wegorzewska
et al. [15] contain the mutant human TDP-43 gene, pre-
ceded by the Flag-tag, under control of the mouse Prnp,
leading to the highest expression in spinal cord and
brain, but also in other tissues. Originally, these mice
were on a mixed C57BL/6 J and CBA background. We
obtained these mice from the Jackson Laboratory, stock
number 010700 (The Jackson Laboratory, Bar Harbor,
Maine, USA). The mice were already backcrossed for 10
generations into a C57BL/6 J background, leading to a
pure C57BL/6 J background. For genotyping, we used
the primers and protocol as previously described [20].
Mice were kept in a conventional facility and fed ad libitum
with dry pellet food (Ssniff® R/M-H, Ssniff Spezialdiäten
GmbH, Soest, Germany) for the non-transgenic (NTG)mice and the TDP-43 (A315T) mice with normal food.
The gel fed mice got DietGel®boost (ClearH20, Maine,
USA) from 30 days on for male and 80 days on for fe-
male mice. This gel food contains all necessary nutri-
ents, but is a soft, high calorie, easily digestible paste
with hardly any fibers.
The mice on gel food were put in cages, without bed-
ding to prevent that wood fibers would stick to their
food. These cages have a grid on the bottom, which al-
lows the stool and urine to pass, but does not cause dif-
ficulties walking. Because of the high grade of humidity
of the gel food, the fur of the mice looked wet. In some
cages mice with the earliest disease onset, lost (part) of
their fur (and whiskers) because of grazing by the others.
This phenomenon does not affect their well-being and
was reversible within 2 weeks after they were put alone
in a cage.
NTG C57BL/6 J mice of both genders were compared
to TDP-43 (A315T) mice with normal food and gel food
for motor performance, body appearance and survival
once a week till onset, than twice a week. Onset of gait
abnormalities was defined as the moment at which a
clear swimming gait appeared, with the paws wide-based
and the animal being unable to hold its lower body from
the ground. End stage (ES) for the TDP-43 (A315T) mice
with normal food was the moment at which the animal
appeared immobile (even after being gently pushed) and
lethargic, since we experienced that in this stage the
death would occur within 24 h. For the gel fed mice, ES
was the moment at which the mouse could not turn
from a side anymore within 30 s. At this point the mice
were euthanized using a lethal dose of 10% Nembutal
and tissues were collected.
Ex-vivo pellet propulsion assay and video analysis of
colonic function
TDP-43 (A315T) female mice of around 90 days were
compared to NTG littermates of the same age (n = 5).
After killing the mice by cervical dislocation, the entire
proximal and distal colon were removed and suspended
in an organ bath (±30 min after death) filled with Krebs
solution (in mM: 120.9 NaCl, 5.9 KCl, 1.2 MgCl2, 2.5
Figure 4 (See legend on next page.)
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Figure 4 Effect of gel food on neurodegeneration in TDP-43(A315T) mice. A: The median disease duration increased for both genders
from 8 days (d) with normal food (n=37) up to 60d (n=46) by gel food (p<0.0001). B: Disease onset is variable: 99-507d in the females (n=18,
median=344d) with normal food, 58-427d in the males (n=22, median=172d); 114-538d (n=38, median=278d) in the females on gel food,
62-366d in the males (n=9, median=118d). The sexual dimorphism stays visible (overall p<0.0001), but there is no significant difference in onset
between the mice on normal versus gel food for each gender. C: No difference (p=0.83) between the average number of motor neurons >300μm2 in
the lumbar spinal cord for NTG (n=6) versus TDP-43 mice with normal food (n=5) versus gel food (n=5) at ES. D: Significant increase in fully denervated
NMJs at ES in the TDP-43 mice on gel food, compared to TDP-43 mice on normal food at ES and NTG mice, n=8/group. E: Gray scale images of the
toluidine-blue staining of the white matter of the distal thoracic spinal cord, where the dorsolateral corticospinal tract axon fibers run, shown for a
NTG mouse (left), an ES TDP-43 mouse with normal food (middle) and gel food (right). Scale bars: 10μm. F: Histogram of results of the counting of the
number of these corticospinal tract axons and their fiber size (n=4/group): the subsequent groups represent a fiber size of 5-15μm2 (bin center 10),
15-25μm2 (bin center 20) and 25–35μm2 (bin center 30). Statistical analysis showed a significant difference in number of fibers (p<0.0001 for
comparison between all group with chi-square test and Bonferroni correction). G: Immunostaining with GFAP of the ventral horn of the spinal
cord of a TDP-43 mouse with normal food (upper) compared to gel food (lower) at ES. Scale bars: 50μm.
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at 37°C and continuously bubbled with 95% O2–5% CO2
(pH 7.4). The intestine was allowed to equilibrate for
30 min, after which an artificial pellet was gently intro-
duced into the proximal colon. Due to the intrinsic peri-
staltic reflex, the pellet was pushed along the intestine
in a consecutive series of individual contraction, which
can be monitored using a video setup. All images were
recorded using custom written routines in Igor pro
(Wavemetrics, Eugene, OR) [33]. The position of the
pellet can be monitored by the dilated diameter (top
images) that is shown as a gray scale line in the spatio-
temporal maps (white arrows) [34]. Frequency and pro-
pulsive force of the contraction can be deduced from
the generated maps.
Histopathologic analyses
Scoring of the NMJ was done as previously described
[35]. Eight mice were analyzed in each group at 100–150
NMJs/mouse.
For the measurement of creatine kinase (CK) levels,
blood was taken from the right atrium after euthanizing,
but before perfusion of the mice (at ES for the TDP-43
(A315T) mice with normal or gel food). The sample was
centrifuged for 10 minutes at 14000 rpm. The super-
natant was pipetted into another eppendorf tube, which
was again centrifuged for 10 minutes at 14000 rpm. This
supernatant was stored at −80°C until all the samples
were collected. CK levels were determined by the same
technique as used for human samples at the laboratory
of UZ Leuven, Belgium.
We performed immunostainings for total (mouse and
human) TDP-43 and glial fibrillary acid protein (GFAP)
on spinal cord of ES (normal or gel fed) TDP-43 (A315T)
mice compared to NTG mice. To this end, mice were
euthanized with 10% Nembutal and perfused with PBS
and 4% PFA. Lumbar spinal cord was dissected and
dehydrated overnight in 30% sucrose in PBS. The tissue
was embedded in Tissue Tek (OCT Compound, 361603E,VWR International, Randor, Pennsylvania, USA) and
frozen at −80°C. Slices of 20 μm were obtained by using
a microtome (Slee cryostat, Mainz, Germany). For
immunostainings, they were blocked with 10% normal
donkey serum (Sigma Aldrich, St Louis, Missouri, USA)
at room temperature, incubated overnight at 4°C with
the C-terminal total (mouse and human) TDP-43 (poly-
clonal rabbit-anti-TDP43-Ab 12892-1-AP, Proteintech,
1/200), followed by incubation with NeuN-Ab (MAB377,
Millipore, Billerica, Massachusetts, USA, 1/200 for 1 h at
room temperature) or incubated for 2 hours at room
temperature with GFAP-Ab (polyclonal rabbit anti-GFAP-
Ab, DAKO, Glostrup, Denmark, 1/500) followed by 3
washes with PBS-T and incubation with the secondary
Ab for 1 h at room temperature [1/500, Alexa Fluor 555
anti-rabbit (for TDP-43-Ab and GFAP-Ab) or Alexa
Fluor 488 anti-mouse (for NeuN), Invitrogen Life Tech-
nologies, Carlsbad, CA, USA]. After 3 washes with PBS-
T, slides were mounted with Vectashield with DAPI and
analyzed using a Zeiss Imager M1 microscope (Zeiss,
Oberkochen, Germany).
To analyze the intestinal tract by immunostainings,
segments of intestine (ileum and colon) were collected,
opened along the mesenteric border and pinned flat in a
sylgard lined dissection dish. Using fine forceps the mu-
cosal and submucosal layers were removed prior to fix-
ation in 4% paraformaldehyde (30 min). After rinsing in
PBS, circular muscle layers were peeled in case of the
small intestine; while for the colon the longitudinal
muscle was removed. Tissues were treated in permeabil-
izing (0.5% triton-x) and 4% goat/donkey serum, prior
to a 24 h (4°C) incubation in primary antibodies: specific
human TDP-43 antibody (monoclonal mouse anti-
hTDP-43-Ab 60019-2-Ig, Proteintech, Chicago, USA,
1/200), total TDP-43 (polyclonal rabbit-anti-TDP43-Ab
12892-1-AP, Proteintech, 1/200), GFAP (Abcam, Cambridge,
UK, 1/5000), NO-synthetase (Santa Cruz biotechnolo-
gies, Santa Cruz, USA, 1/400), ChAT (Chemicon Inter-
national, 1/500) and HuCD (Invitrogen Life Technologies,
Figure 5 (See legend on next page.)
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Figure 5 Progressive loss of NOS neurons in TDP-43 (A315T) mice with gel food. A: (left) The graph shows the NOS/HuCD neurons ratio in
NTG (color code: blue; n = 7), TDP-43 (A315T) on normal food (color code: red; n = 4) and TDP-43 (A315T) on gel food (color code: green; n = 3)
mice. (right) The histogram (and color matched Gaussian fits) displays the size of NOS neurons (in μm2) in NTG (color code: blue; n = 7), TDP-43
(A315T) normal fed (color code: red; n = 4) and TDP-43 (A315T) gel fed (color code: green; n = 3) mice, showing an enlargement of the remaining
NOS neurons in TDP-43 (A315T) mice on normal food and even worse so in gel fed TDP-43 (A315T) mice. B: Immunostaining revealed
enlargement of NOS neurons (white arrows; color code: blue) and distortion (white arrowheads) of glial network (GFAP in red) in TDP-43 (A315T)
mice on gel food. Neurons were stained with panneuronal marker HuCD (color code: green). Scale bars: 100 μm.
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secondary antibodies were added for 2 h. Immunohisto-
chemical staining was visualized under an epifluores-
cence microscope (BX 41 Olympus, Belgium) with
specific filter cubes (EX/DM/EM in nm) for blue (325-
375/400/435-485), green (460-495/505/510-550) and red
fluorescent probes (570-590/595/600-660). Images were
recorded using Cell^F software on an XM10 (Olympus)
camera.
For counting of motor neurons, the lumbar spinal
cord was cut in 20 μm thick slices, with each 6th slice
placed on a slide (10 in total along the whole lumbar re-
gion). These were stained by Cresylviolet (Sigma). After
taking photos of the ventral horns at 40x (10/mouse)
with a Zeiss Imager M1 microscope (Zeiss), manual
counting and analyses of the size of motor neurons was
done with use of AxioVision (Zeiss). Six NTG mice, 5
ES TDP-43 (A315T) mice with normal food and 5 ES
TDP-43 (A315T) mice with gel food were analyzed.
Staining and quantification of the dorsolateral corti-
cospinal tract axons in the distal thoracic spinal cord
(of 4 NTG, 4 ES TDP-43 (A315T) mice on normal food
and 4 ES mice on gel food) was done as described by
Wegorzewska et al. [15].
Western blot and qPCR
Spinal cord and brain from presymptomatic TDP-43
(A315T) or NTG mice (n = 3 for each genotype) were
collected in Tripure isolation reagent (Roche Diagnos-
tics, IN, USA) or tissue protein extraction reagents
(Thermo Scientific, Rockford, IL, USA) with Complete
(Complete EDTA-free, Roche Diagnostics) for qPCR and
Western blot respectively.
RNA extraction was performed as described previously
[36]. qPCR assays were run in triplicate with n = 3 for each
condition. The mRNA expression in spinal cord and brain
of mouse TDP-43 (Mm.PT.51.5553804 Tardp exon 2–3,
IDT, Coralville, Iowa, USA) was compared to the expres-
sion of several housekeeping genes, using taqman assays:
beta-actin (VIC-MGB 4352341E-0905010, Applied Biosys-
tems, Life Technologies, CA, USA), mouse hypoxanthine-
guanine phosphoribosyltransferase (Mm01545399_m1
Hprt, Applied Biosystems) and mouse glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Mm.PT.39a.1
GAPDH exon 2–3, IDT, Leuven, Belgium). Expressionof mouse Sort1 + Ex17b mRNA in the brain of TDP-43
(A315T) and NTG mice was determined using Cyber
green. The primers were: mouse Sort1 + Ex17b: 5′-AAAT
CCCAGGAGACAAATGC-3′ and 5′-GAGCTGGATTC
TGGGACAAG-3′; mouse GAPDH: 5′- TGGCCTTCCG
TGTTCCTAC -3′ and 5′- GAGTTGCTGTTGAAGTCG
CA -3′.
For Western blot, 40 μg of spinal cord of TDP-43
(A315T) or NTG mice (n = 3 for each condition) were
blotted using a precast gel (NuPAGE®Bis-Tris gel IM-
8042, Novex, Life technologies, Carlsbad, California,
USA) and following the protocol described in Van
Hoecke et al. [37], allowing separation of the mouse
TDP-43 (of 43 kDa) and the exogenous human TDP-43,
with the Flag-tag running at a slightly higher molecular
weight as described in Wegorzewska et al. [15]. The
membranes were probed with polyclonal rabbit-anti-
TDP43-Ab (12892-1-AP, Proteintech, 1/500). The mouse
TDP-43 levels were compared between TDP-43 (A315T)
mice and NTG mice. Alfa-tubulin (mouse anti-alfa-
tubulin, T6199, Sigma, 1/5000) was used as a loading
control. Also, the total TDP-43 expression between
90 days old TDP-43 (A315T) males and females was
compared by using the polyclonal rabbit-anti-TDP43-
Ab (12892-1-AP, Proteintech, 1/500) and normalized
against mouse GAPDH (mouse anti-GAPDH AM4300,
Ambion, Life Technologies, 1/5000).
Statistics
Data are presented as mean ± standard error of the
mean, except for Figure 3E and F in which the standard
deviations are shown. All statistics were performed using
Graph Path Prism or Stats Direct software. In case of
not normally distributed values, a non parametric test
was used to compare 2 groups. For more than 2 groups,
an Anova or Kruskal-Wallis (in case of not normally dis-
tributed data) was used. Survival data were analyzed
using the log-rank test.
Additional file
Additional file 1: Movies 1–4: Motor phenotype of symptomatic
and ES TDP-43 (A315T) mice. Difference in gait abnormalities between
the TDP-43 (A315T) mouse on normal food (additional movie 1.vc),
compared to one on gel food (additional movie 2.vc). The swimming gait
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an ES situation, as is visible in movie 4 (additional movie 4.MOV). The
mouse is not able to turn from its side anymore due to the severe
neurologic impairment, whereas the TDP-43 (A315T) mouse on normal
food in movie 3 (additional movie 3.MOV) is about to die due to
intestinal pseudo-obstruction.
Abbreviations
TDP-43: TAR DNA-binding protein 43; ALS: Amyotrophic lateral sclerosis;
FTLD: Frontotemporal lobar degeneration; NTG: Non-transgenic; CK: Creatine
kinase; ES: Endstage; GFAP: Glial fibrillary acid protein; Prnp: Prion promoter;
NOS: Nitric-oxide synthase; ChAT: Choline acethyltransferase;
NMJ: Neuromuscular junctions; ENS: Enteric nervous system; Sort1 +
ex17b: Sortilin 1 including exon 17b.
Competing interests
The authors declare that they have no competing interests. All experiments
on rodents were approved by the local ethical committee of the University
of Leuven, Belgium.
Authors’ contributions
SH carried out the breeding, genotyping, perfusions, qPCRs, Western blots,
motor assessment, immunoassays and histopathology of the spinal cord and
NMJs of the mice, as well as the quantifications and statistical analysis of
these results. SH drafted the manuscript. CC has helped substantially to
acquisition, analysis and interpretation of data on intestinal assays and in
drafting the manuscript. PVD and PVB participated in the design and
coordination of the studies and helped to analysis and interpretation of data
and in drafting the manuscript. LVDB and WR have been involved in revising
the manuscript. All authors read and approved the manuscript.
Authors’ information
Pieter Vanden Berghe and Philip Van Damme share last senior authorship.
Acknowledgements
This work was supported by grants from the University of Leuven (GOA
11/014, STRT1/10/046), the Belgian government (Interuniversity Attraction
Poles, program P7/16 of the Belgian Federal Science Policy Office) and the
European Community’s Health Seventh Framework Program (FP7/2007-2013
[259867]), the ALS therapy alliance, the Belgian ALS league, and the ABMM.
S.H. holds a PhD fellowship, C.C. is a postdoctoral fellow and P.V.D. a senior
clinical investigator of the FWO-Vlaanderen. PVD and PVB are supported by
FWO-Vlaanderen (G.0501.10). W.R. is supported through the E. von Behring
Chair for Neuromuscular and Neurodegenerative Disorders and holds an ERC
Advanced Grant (340429).
We would like to thank the members of LENS for expert technical assistance
and discussion. Part of the microscopy was performed in the Cell Imaging
Core (funded by the Hercules foundation, 2009–2011).
Author details
1KU Leuven - University of Leuven, Department of Neurosciences,
Experimental Neurology and Leuven Research Institute for Neuroscience and
Disease (LIND), Leuven, Belgium. 2VIB, Vesalius Research Center, Laboratory of
Neurobiology, Leuven, Belgium. 3University Hospitals Leuven, Department of
Neurology, Leuven, Belgium. 4Laboratory for Enteric NeuroScience (LENS),
Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven,
Leuven, Belgium.
Received: 10 March 2014 Accepted: 6 June 2014
Published: 17 June 2014
References
1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT,
Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E,
Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee
VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 2006, 314:130–133.
2. Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R,
Graff-Radford NR, Hutton ML, Dickson DW: TDP-43 immunoreactivity in
hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 2007, 61:435–445.3. Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, Yamazaki
M, Oyanagi K: TDP-43 is deposited in the Guam parkinsonism-dementia
complex brains. Brain 2007, 130:1386–1394.
4. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL: Colocalization of
transactivation-responsive DNA-binding protein 43 and huntingtin in
inclusions of Huntington disease. J Neuropathol Exp Neurol 2008,
67:1159–1165. doi:10.1097/NEN.0b013e31818e8951.
5. Lee EB, Lee VM, Trojanowski JQ: Gains or losses: molecular mechanisms of
TDP43-mediated neurodegeneration. Nat Rev Neurosci 2012, 13:38–50.
doi:10.1038/nrn3121.
6. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde
C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W,
Meininger V, Dupre N, Rouleau GA: TARDBP mutations in individuals with
sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008,
40:572–574. doi:10.1038/ng.132.
7. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S,
Durnall JC, Williams KL, Buratti E, Baralle F, De Belleroche J, Mitchell JD,
Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE: TDP-43 mutations
in familial and sporadic amyotrophic lateral sclerosis. Science 2008,
319:1668–1672. doi:10.1126/science.1154584.
8. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB, Clay D,
Wood EM, Chen-Plotkin AS, Martinez-Lage M, Steinbart E, McCluskey L,
Grossman M, Neumann M, Wu IL, Yang WS, Kalb R, Galasko DR, Montine TJ,
Trojanowski JQ, Lee VM, Schellenberg GD, Yu CE: TARDBP mutations in
amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and
histopathological analysis. Lancet Neurol 2008, 7:409–416. doi:10.1016/
S1474-4422(08)70071-1.
9. Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M,
Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA,
Da Cruz S, Clutario KM, Swing D, Tessarollo L, Marsala M, Shaw CE, Yeo GW,
Cleveland DW: ALS-linked TDP-43 mutations produce aberrant RNA
splicing and adult-onset motor neuron disease without aggregation or
loss of nuclear TDP-43. Proc Natl Acad Sci U S A 2013, 110:E736–E745.
doi:10.1073/pnas.1222809110.
10. Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J,
Xu Y, Winton MJ, Trojanowski JQ, Lee VM: Dysregulation of the ALS-
associated gene TDP-43 leads to neuronal death and degeneration in
mice. J Clin Invest 2011, 121:726–738. doi:10.1172/JCI44867.
11. Shan X, Chiang PM, Price DL, Wong PC: Altered distributions of Gemini of
coiled bodies and mitochondria in motor neurons of TDP-43 transgenic
mice. Proc Natl Acad Sci U S A 2010, 107:16325–16330. doi:10.1073/
pnas.1003459107.
12. Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL: Progressive
motor weakness in transgenic mice expressing human TDP-43.
Neurobiol Dis 2010, 40:404–414. doi:10.1016/j.nbd.2010.06.017.
13. Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien JP:
Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal
lobar degeneration in transgenic mice produced with TDP-43 genomic
fragments. Brain 2011, 134:2610–2626. doi:10.1093/brain/awr159.
14. Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP, Fu
WM, Shen CK: Elevated expression of TDP-43 in the forebrain of mice is
sufficient to cause neurological and pathological phenotypes mimicking
FTLD-U. J Exp Med 2010, 207:1661–1673. doi:10.1084/jem.20092164.
15. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH: TDP-43 mutant
transgenic mice develop features of ALS and frontotemporal lobar
degeneration. Proc Natl Acad Sci U S A 2009, 106:18809–18814.
doi:10.1073/pnas.0908767106.
16. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V,
Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S: TDP-43
transgenic mice develop spastic paralysis and neuronal inclusions
characteristic of ALS and frontotemporal lobar degeneration. Proc Natl
Acad Sci U S A 2010, 107:3858–3863. doi:10.1073/pnas.0912417107.
17. Xu YF, Gendron TF, Zhang YJ, Lin WL, D’Alton S, Sheng H, Casey MC, Tong
J, Knight J, Yu X, Rademakers R, Boylan K, Hutton M, McGowan E, Dickson
DW, Lewis J, Petrucelli L: Wild-type human TDP-43 expression causes
TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and
early mortality in transgenic mice. J Neurosci 2010, 30:10851–10859.
doi:10.1523/JNEUROSCI.1630-10.2010.
18. Xu YF, Zhang YJ, Lin WL, Cao X, Stetler C, Dickson DW, Lewis J, Petrucelli L:
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic
mice. Mol Neurodegener 2011, 6:73. doi:10.1186/1750-1326-6-73.
Herdewyn et al. Molecular Neurodegeneration 2014, 9:24 Page 14 of 14
http://www.molecularneurodegeneration.com/content/9/1/2419. Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M: Premature death of
TDP-43 (A315T) transgenic mice due to gastrointestinal complications
prior to development of full neurological symptoms of amyotrophic
lateral sclerosis. Int J Exp Pathol 2013, 94:56–64. doi:10.1111/iep.12006.
20. Guo Y, Wang Q, Zhang K, An T, Shi P, Li Z, Duan W, Li C: HO-1 induction in
motor cortex and intestinal dysfunction in TDP-43 A315T transgenic
mice. Brain Res 2012, 1460:88–95. doi:10.1016/j.brainres.2012.04.003.
21. Medina DX, Orr ME, Oddo S: Accumulation of C-terminal fragments of
transactive response DNA-binding protein 43 leads to synaptic loss and
cognitive deficits in human TDP-43 transgenic mice. Neurobiol Aging
2014, 35:79–87. doi:10.1016/j.neurobiolaging.2013.07.006.
22. Tsuji H, Nonaka T, Yamashita M, Masuda-Suzukake M, Kametani F, Akiyama
H, Mann DM, Tamaoka A, Hasegawa M: Epitope mapping of antibodies
against TDP-43 and detection of protease-resistant fragments of
pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal
lobar degeneration. Biochem Biophys Res Commun 2012, 417:116–121.
doi:10.1016/j.bbrc.2011.11.066.
23. Ayala YM, De Conti L, Avendaño-Vázquez SE, Dhir A, Romano M,
D’Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, Baralle FE: TDP-43
regulates its mRNA levels through a negative feedback loop.
EMBO J 2011, 30:277–288. doi:10.1038/emboj.2010.310.
24. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY,
Ling SC, Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y,
Donohue JP, Shiue L, Bennett CF, Yeo GW, Cleveland DW: Long pre-mRNA
depletion and RNA missplicing contribute to neuronal vulnerability from
loss of TDP-43. Nat Neurosci 2011, 14:459–468. doi:10.1038/nn.2779.
25. Xu YF, Prudencio M, Hubbard JM, Tong J, Whitelaw EC, Jansen-West K,
Stetler C, Cao X, Song J, Zhang YJ: The pathological phenotypes of human
TDP-43 transgenic mouse models are independent of downregulation of
mouse Tdp-43. PLoS One 2013, 8:e69864. doi:10.1371/journal.pone.0069864.
26. Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang YJ, Xu YF, Gass J,
Stuani C, Stetler C, Rademakers R, Dickson DW, Buratti E, Petrucelli L:
Misregulation of human sortilin splicing leads to the generation of a
nonfunctional progranulin receptor. Proc Natl Acad Sci U S A 2012,
109:21510–21515. doi:10.1073/pnas.1211577110.
27. Steward O, Zheng B, Ho C, Anderson K, Tessier-Lavigne M: The dorsolateral
corticospinal tract in mice: an alternative route for corticospinal input to
caudal segments following dorsal column lesions. J Comp Neurol 2004,
472:463–477.
28. Albanese V, Lawson VA, Hill AF, Cappai R, Di Guardo G, Staikopoulos V,
Thacker M, Furness JB, Chiocchetti R: Evidence for prion protein
expression in enteroglial cells of the myenteric plexus of mouse
intestine. Auton Neurosci 2008, 140:17–23. doi:10.1016/j.autneu.2008.01.008.
29. Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C,
Osborne M, Austin A, Vieira FG, Lutz C, Perrin S: C57BL/6J congenic
Prp-TDP43A315T mice develop progressive neurodegeneration in the
myenteric plexus of the colon without exhibiting key features of ALS.
Brain Res 2013. doi:10.1016/j.brainres.2013.10.013.
30. Natale G, Pasquali L, Paparelli A, Fornai F: Parallel manifestations of
neuropathologies in the enteric and central nervous systems.
Neurogastroenterol Motil 2011, 23:1056–1065. doi:10.1111/j.1365-
2982.2011.01794.x.
31. Clarke CM, Plata C, Cole B, Tsuchiya K, La Spada AR, Kapur RP: Visceral
neuropathy and intestinal pseudo-obstruction in a murine model of a
nuclear inclusion disease. Gastroenterology 2007, 133:1971–1978.
32. Cirillo C, Tack J, Vanden Berghe P: Nerve activity recordings in routine
human intestinal biopsies. Gut 2013, 62:227–235. doi:10.1136/gutjnl-2011-
301777.
33. Sasselli V, Boesmans W, Vanden Berghe P, Tissir F, Goffinet AM, Pachnis V:
Planar cell polarity genes control the connectivity of enteric neurons.
J Clin Invest 2013, 123:1763–1772. doi:10.1172/JCI66759.
34. Hennig GW, Costa M, Chen BN, Brookes SJ: Quantitative analysis of
peristalsis in the guinea-pig small intestine using spatio-temporal maps.
J Physiol 1999, 517:575–590.
35. Herdewyn S, De Muynck L, Van Den Bosch L, Robberecht W, Van Damme P:
Progranulin does not affect motor neuron degeneration in mutant SOD1
mice and rats. Neurobiol Aging 2013, 34:2302–2303.
doi:10.1016/j.neurobiolaging.2013.03.027.36. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, Van
Damme P, Auwerx J, Robberecht W: Hdac6 deletion delays disease
progression in the SOD1G93A mouse model of ALS. Hum Mol Genet 2013,
22:1783–1790. doi:10.1093/hmg/ddt028.
37. Van Hoecke A, Schoonaert L, Lemmens R, Timmers M, Staats KA, Laird AS,
Peeters E, Philips T, Goris A, Dubois B, Andersen PM, Al-Chalabi A, Thijs V,
Turnley AM, Van Vught PW, Veldink JH, Hardiman O, Van Den Bosch L,
Gonzalez-Perez P, Van Damme P, Brown RH Jr, van den Berg LH, Robberecht
W: EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal
models and in humans. Nat Med 2012, 18:1418–1422.
doi:10.1186/1750-1326-9-24
Cite this article as: Herdewyn et al.: Prevention of intestinal obstruction
reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice.
Molecular Neurodegeneration 2014 9:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
